Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Diisononyl adipate (DINA) is a plasticizer used in PVC products as an alternative for restricted phthalate plasticizers. With this study, we provide first data on human DINA metabolism and excretion. We postulated mono(hydroxy-isononyl) adipate (OH-MINA), mono(oxo-isononyl) adipate (oxo-MINA), and mono(carboxy-isooctyl) adipate (cx-MIOA) as specific DINA metabolites based on the known human metabolism of structurally similar adipates and phthalates. Urinary excretion was quantitatively investigated after a single oral dose (113 to 145 µg/kg body weight) to three healthy volunteers using a newly developed online-SPE-LC-MS/MS method with isotope dilution and LOQs between 0.3 - 0.6 µg/L. OH-MINA turned out to be the major of the three metabolites with consistent urinary excretion fractions (Fs) of 0.020-0.023 % among all volunteers. Oxo-MINA and cx-MIOA were excreted with lower shares (mean: 0.003 % and 0.009 %, respectively). For all three metabolites, urinary concentrations peaked quickly between 1.4 and 2.3 h post dose with maximum concentrations of 23.1 (OH-MINA), 2.87 (oxo-MINA) and 9.83 µg/L (cx-MIOA). Thus, Fs and urinary concentrations were rather low for these specific metabolites, with the major share of the dose presumably being excreted as non-specific metabolites such as adipic acid. In a pilot population (n=35) of German adults without known DINA exposure, we could not detect any of the three metabolites, contrary to the dosage study, indicating to population exposures lower than 50 µg/kg body weight/day. The new HBM method in conjunction with the new Fs can be used for objective DINA exposure and risk assessment especially in populations with potentially higher DINA exposures.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7975632PMC
http://dx.doi.org/10.17179/excli2021-3360DOI Listing

Publication Analysis

Top Keywords

urinary excretion
12
three metabolites
12
diisononyl adipate
8
adipate dina
8
µg/kg body
8
urinary concentrations
8
dina exposure
8
metabolites
7
dina
7
urinary
5

Similar Publications

Introduction: Knockout of the Fmo5 gene in mice led to a lean, slow-ageing phenotype characterised by the presence of 2,3-butanediol isomers in their urine and plasma. Oral treatment of wildtype mice with 2,3-butanediol led to a low cholesterol, low epididymal fat phenotype.

Objectives: Determine if significant, heterozygous coding variations in human FMO5 would give rise to similar clinical and metabolic phenotypes in humans, as in C57BL/6J mice with knockout of the Fmo5 gene and in particular, increased excretion of 2,3-butanediol.

View Article and Find Full Text PDF

The consumption of kombu plays an important role in the traditional dietary habits of East-Asian countries. However, data on the metabolic profile of kombu-derived iodine remain limited. Totally, 20 Chinese participants (age 19.

View Article and Find Full Text PDF

Optimizing Linezolid Dosing for Nosocomial Urinary Tract Infections in Critically Ill Patients with Renal Impairment.

Int J Antimicrob Agents

September 2025

Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China; National Key Laboratory of Advanced Drug Formulations for Overcoming Delivery Barriers, Fudan University, Shanghai, China. Electronic address:

Background: This study characterized the urinary pharmacokinetics and pharmacodynamics (PK/PD) of linezolid (LNZ) in critically ill patients with renal impairment and nosocomial multidrug-resistant Gram-positive urinary tract infections (UTIs). The aim was to address therapeutic challenges arising from limited treatment options and uncertain urinary excretion, to establish optimized dosing strategies.

Methods: A prospective observational study was conducted in ICU patients with renal impairment.

View Article and Find Full Text PDF

A novel treatment for diabetic nephropathy: Folate receptor-targeted delivery of TLR4 siRNA via functionalized PLGA nanoparticles in streptozotocin-induced diabetic murine models.

Nanomedicine

September 2025

The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730000, Gansu, People's Republic of China; Department of Nephrology, The Second Hospital & Clinical Medical School, Lanzhou University, Lanzhou, 730030, Gansu, People's Republic of China; Key laboratory of nephropathy, The S

Diabetic kidney disease (DKD), a prominent microvascular complication of diabetes mellitus and the leading cause of end-stage renal disease (ESRD), was addressed through a novel nanotherapeutic approach. This study engineered folic acid-conjugated poly(lactic-co-glycolic acid) nanoparticles (FA-PLGA NPs) for the folate receptor (FR)-targeted delivery of Toll-like receptor 4 small interfering RNA (TLR4 siRNA) to treat diabetic nephropathy (DN). In a streptozotocin-induced DN murine model, administration of FA-PLGA NPs/TLR4 siRNA significantly mitigated renal injury compared to untreated DN controls.

View Article and Find Full Text PDF

Huangkui capsules for diabetic nephropathy: Comprehensive review of efficacy and molecular mechanisms.

Phytomedicine

August 2025

Center for Clinical Reseach, Guangdong Provincial Hospital of Chinese Medicine, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510120, China. Electronic address:

Background: The management of kidney diseases urgently needs additional therapeutic options. Encouraging evidence suggests the efficacy of Huangkui capsules (HKCs), a plant-derived traditional medicine, in treating various subtypes of nephropathy. However, current evidence is fragmented between clinical outcomes and mechanistic insights.

View Article and Find Full Text PDF